Claims
- 1. A method for prevention or treatment of gingivitis or soft tissue aspects of periodontitis comprising topical administration, to gingival tissues of the oral cavity, of a fluoride toothpaste of a composition comprising a safe and effective amount of a selective H-2 antagonist.
- 2. The method of claim 1 wherein the selective H-2 antagonist is selected from the group consisting of cimetidine, etintidine, ranitidine, ICIA-5165, tiotidine, ORF-17578, lupitidine, donetidine, famotidine, roxatidine, pifatidine, lamtidine, BL-6548, BMY-25271, zaltidine, nizatidine, mifentidine, BMY-52368, SKF-94482, BL-6341A, ICI-162846, ramixotidine, Wy-45727, SR-58042, BMY-25405, loxtidine, DA-4634, bisfentidine, sufotidine, ebrotidine, HE-30-256, D-16637, FRG-8813, FRG-8701, impromidine, L-643728, and HB-408.
- 3. The method of claim 1 wherein the selective H-2 antagonist is selected from the group consisting of cimetidine, ranitidine, famotidine, roxatidine, nizatidine and mifentidine.
- 4. The method of claim 1 wherein the selective H-2 antagonist is selected from the group consisting of cimetidine, ranitidine, famotidine, and nizatidine.
- 5. The method of claim 1 wherein the selective H-2 antagonist is cimetidine.
- 6. The method of claim 1 wherein the selective H-2 antagonist is ranitidine.
- 7. The method of any of claims 1, 4, 5 and 6 wherein the composition comprises from about 0.01% to about 10% of the selective H-2 antagonist.
- 8. A fluoride toothpaste or toothpaste or tooth gel composition comprising:
- (a) a safe and effective amount of a selective H-2 antagonist; and
- (b) a toothpaste or tooth gel carrier comprising a dental abrasive, a surfactant, a humectant, a flavoring or sweetening agent, and
- (c) a safe and effective amount of a fluoride anticaries agent water.
- 9. The composition of claim 8 wherein the selective H-2 antagonist is selected from the group consisting of cimetidine, etintidine, ranitidine, ICIA-5165, tiotidine, ORF-17578, lupitidine, donetidine, famotidine, roxatidine, pifatidine, lamtidine, BL-6548, BMY-25271, zaltidine, nizatidine, mifentidine, BMY-52368, SKF-94482, BL-6341A, ICI-162846, ramixotidine, Wy-5727, SR-58042, BMY-25405, loxtidine, DA-4634, bisfentidine, sufotidine, ebrotidine, HE-30-256, D-16637, FRG-8813, FRG-8701, impromidine, L-643728, and HB-408.
- 10. The compositions of claim 9 wherein the selective H-2 antagonist is selected from the group consisting of cimetidine, ranitidine, famotidine, roxatidine, nizatidine and mifentidine.
- 11. The composition of claim 9 wherein the selective H-2 antagonist is selected from the group consisting of cimetidine, ranitidine, famotidine and nizatidine.
- 12. The composition of claim 9 wherein the selective H-2 antagonist is cimetidine.
- 13. The composition of claim 9 wherein the selective H-2 antagonist is ranitidine.
Parent Case Info
This is a continuation-in-part of application Ser. No. 07/868,805, filed on Apr. 15, 1992.
US Referenced Citations (25)
Foreign Referenced Citations (2)
Number |
Date |
Country |
950833 |
Jul 1974 |
CAX |
0241179 |
Oct 1987 |
EPX |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
868805 |
Apr 1992 |
|